News

1 2 3 4
NEWS

SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

  • SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need.
  • Collaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors.
  • Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million.
NEWS

Acquisition agreement with Boehringer Ingelheim for NBE-Therapeutics marks first major biotech exit for PPF Group

  • €1.18 billion acquisition provides for significant returns to PPF Group as NBE’s largest shareholder
  • SOTIO, a clinical stage immuno-oncology company, and a member of PPF Group, continues development of two ADC products under the collaboration with NBE

PPF Group, an international investment group, today announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The lead program NBE-002, an iADC targeting ROR1, entered the Phase 1 clinical testing in 2020. 

NEWS

SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to develop next-generation antibody-drug conjugates

Basel, Switzerland & Prague, Czech Republic – November 7, 2019  NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate (ADC) under their existing license and collaboration agreement. NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of this second undisclosed target. The development will be based on NBE’s proprietary antibody drug conjugate platform, including NBE’s site-specific SMAC-technologyTM conjugation and its new, highly potent anthracycline toxin platforms. SOTIO will take global responsibility for clinical development, registration and commercialization of the ADC products.